A new international, randomized clinical trial is evaluating a vaccine developed to protect against 21 strains of pneumococcus, up from the current 13 strains covered now. That means greater protection to babies against the common infection that causes pneumonia, sinusitis and meningitis.Pneumococcal disease can lead to serious illness and death among children under two years of age. The US had 31,000 cases and more than 3,500 deaths from invasive pneumococcal disease (bacteremia and meningitis)Participants will receive four doses of the vaccine at two, four, and six months of age and a booster dose at 12-15 months. The new vaccine would cover the most common ones of the over 90 different strains known so far.First things first, as always, is safety and efficacy, and that is the role of clinical trials. Participants will be enrolled in the study for up to 19 months, which will also include three blood tests.